Compare Deutsche Bank AG (DB) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deutsche Bank AG vs Incyte Corporation — how do they compare? Deutsche Bank AG trades at $38.26 (market cap $71.96B), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Deutsche Bank AG is far larger — about 2.9× Incyte Corporation's market cap, and Deutsche Bank AG pays a 3.04% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| DB | INCY | |
|---|---|---|
Market Cap | $71.96B | $24.54B |
Sector | Financials | Health |
52-Week High | $40.33 | $129.93 |
52-Week Low | $28.37 | $81.61 |
Dividend Yield | 3.04% | — |
Enterprise Value | — | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deutsche Bank (DB) trades at $38.51, up 0.63% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals: a low P/E of 10.07 and P/B of 0.79, with net income margin improving to 21.59% in 2025. Recent Q2 2026 earnings missed estimates but revenue growth remains robust, supported by a new share buyback plan and its role as a renminbi clearing bank in China, as reported by Reuters on August 10, 2026.
The outlook is mixed: valuation discounts and earnings beats in three of the last four quarters signal upside potential, but a neutral analyst consensus (57.58% hold) and regulatory risks from tax investigations pose headwinds. Investors should weigh strong operational cash flow of $47.06B in 2025 against volatile net income trends and high RSI levels indicating overbought conditions.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
